Translating Biomarkers of Cholangiocarcinoma for Theranosis: A Systematic Review

Cholangiocarcinoma (CCA) is a rare disease with poor outcomes and limited research efforts into novel treatment options. A systematic review of CCA biomarkers was undertaken to identify promising biomarkers that may be used for theranosis (therapy and diagnosis). MEDLINE/EMBASE databases (1996-2019)...

Full description

Saved in:
Bibliographic Details
Published inCancers Vol. 12; no. 10; p. 2817
Main Authors Wijetunga, Imeshi, McVeigh, Laura E, Charalambous, Antonia, Antanaviciute, Agne, Carr, Ian M, Nair, Amit, Prasad, K Raj, Ingram, Nicola, Coletta, P Louise
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 30.09.2020
MDPI
Subjects
Bile ducts
Bioinformatics
Biomarkers
Cancer
Cancer therapies
Cholangiocarcinoma
Diagnosis
Disease
Gelatinase B
Genes
Genetic translation
Growth factors
Health aspects
Medical prognosis
Nanoparticles
Nanotechnology
Ontology
Proteins
Rare diseases
Review
Reviews
Systematic review
Japan
therapy and diagnosis
theranosis
cholangiocarcinoma
biomarkers
biomarker selection
Online AccessGet full text

Cover

More Information
Summary:Cholangiocarcinoma (CCA) is a rare disease with poor outcomes and limited research efforts into novel treatment options. A systematic review of CCA biomarkers was undertaken to identify promising biomarkers that may be used for theranosis (therapy and diagnosis). MEDLINE/EMBASE databases (1996-2019) were systematically searched using two strategies to identify biomarker studies of CCA. The PANTHER Go-Slim classification system and STRING network version 11.0 were used to interrogate the identified biomarkers. The TArget Selection Criteria for Theranosis (TASC-T) score was used to rank identified proteins as potential targetable biomarkers for theranosis. The following proteins scored the highest, CA9, CLDN18, TNC, MMP9, and EGFR, and they were evaluated in detail. None of these biomarkers had high sensitivity or specificity for CCA but have potential for theranosis. This review is unique in that it describes the process of selecting suitable markers for theranosis, which is also applicable to other diseases. This has highlighted existing validated markers of CCA that can be used for active tumor targeting for the future development of targeted theranostic delivery systems. It also emphasizes the relevance of bioinformatics in aiding the search for validated biomarkers that could be repurposed for theranosis.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers12102817